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ABSTRACT  
Hogg, Brendan, M.S., Spring 2018            Health and Human Performance 
Interleukin-6, a novel myokine 
Chairperson: John C. Quindry, PhD 
Interleukin-6 (IL-6) was first identified as a pleiotropic cytokine, with a host of body-wide 
functions. Cytokine functions are characterized by chronically elevated levels within various 
inflammatory states. In this regard, IL-6 is largely associated with the acute phase response to 
many stimuli and performs specific actions when produced from certain cell types. Accrued 
evidence indicates IL-6 release from skeletal muscle often includes myokine functions.  Novel 
myokine functions are adaptive in nature, and as compared to inflammatory/cytokine roles, exhibit 
a transient time course. Following exercise plasma IL-6 peaks and returns to resting levels within 
1-2 hours. In contrast, IL-6 is observed to be consistently elevated in a much longer time course 
during inflammatory disease states. Production and release of IL-6 is reliant on many stress 
dependent factors, but from a skeletal muscle perspective, the release appears to be 
bioenergetic/fatigue dependent. Moreover, long duration in conjunction with high intensity 
exercise results in the greatest IL-6 production. Association between IL-6 and the metabolic status 
of skeletal muscle, in regards to glycogen content and glucose uptake, has provided a new avenue 
of research. The acute increase in circulating IL-6 following exercise indicates divergent roles for 
IL-6. Recent evidence indicates that IL-6 exerts regulatory cyto-protection in regards to insulin 
sensitivity and metabolic stress. In addition, recent data suggest that IL-6 is central within 
mechanisms regarding cardio-protection from ischemic injury. Given these widespread benefits, 
there is reason to suspect additional myokine roles of IL-6 are on the horizon.  Further research 
efforts with mechanistic approaches should be directed toward investigating skeletal muscle 
derived IL-6 in regards to exercise-induced protection from metabolic and ischemic injury.   
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Interleukin-6 (IL-6): Cytokine Vs Myokine 
 Over the last decade investigations designed to target interleukin-6 (IL-6) provide new 
understanding of health and disease progression. Overarching conclusions reveal that interleukin-
6 is largely associated with inflammatory and auto-immune processes observed in various diseases 
such as diabetes, atherosclerosis, systemic lupus erythematosus and rheumatoid arthritis 
(Kristiansen & Mandrup-Poulsen, 2005; Dubiński, et al., 2007; Tackey et al., 2004; Nishimoto, et 
al., 2006). Moreover, mechanistic studies report that IL-6 overexpression leads to systemic 
inflammation, altered metabolic function as well as severe liver inflammation (Franckhauser, et 
al., 2008). IL-6 is not exclusively observed in detrimental disease states as evidenced by its acute 
appearance in circulation during and following exercise. Furthermore, ample evidence exists 
indicating that IL-6 possesses anti-inflammatory and even cyto-protective properties (Pedersen, 
2017). IL-6 communicates with various cell types, in turn exerting systemic effects, which 
highlight a far-reaching influence within human biology (Kishimoto, 1992). The initially 
perplexing and pleiotropic characteristics of IL-6 have recently been revealed within the context 
of health and disease.  
Cytokine research provides a better understanding of homeostatic function and disease 
progression. Cytokines are signaling proteins produced from a variety of immune cells and act in 
paracrine, autocrine and endocrine manners influencing the adaptive and innate immune systems 
(Kian Fan Chung, 2009). IL-6 is one of the most extensively documented cytokines, with attention 
being justified due to its ubiquitous nature and chronic elevation within various inflammatory 
disease states. Interleukin-6 was first identified in 1980 after researchers aimed to clone the 
interferon (IFN)-β gene within human fibroblasts (Weissenbach, et al., 1980; Van Snick, et al., 
1990). However, it was not until 1989 that researchers came to agreement and labeled the 
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mysterious protein “interleukin-6” (Akira, et al., 1993). Early evidence suggested appearance of 
IL-6 in circulation was mainly the result of stimulated immune cells such as macrophages, 
fibroblasts, as well as T-cells, B-cells, and white blood cells (Andus, et al., 1998; Akira, et al., 
1993). IL-6 production from immune cells and subsequent action is influenced by the presence of 
other pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-1β 
(IL-1β). Ample evidence supports a cytokine role of IL-6 in the host defense mechanism/acute 
phase response to trauma, burns and infection; hematopoiesis and stimulating the synthesis and 
release of acute phase proteins and antibodies (Andus, et al., 1988; Tanaka, Narazaki and 
Kishimoto, 2014). Due to the association between IL-6 and inflammatory states, it is 
understandable that early published findings promoted the notion that plasma IL-6 elevations in 
response to exercise were a result of tissue damage and inflammatory processes.  
IL-6 release following exercise is not dependent on muscle damage. Initial findings of 
increased circulating IL-6 concentrations post-exercise were first observed by Northoff & Berg in 
1991. In the context of the conventional understanding of IL-6 as an important moderator in 
immune cell function and proliferation, the increase in IL-6 post-exercise was thought to be due 
to immune cell recruitment following muscle damage. Bruunsgaard et al., (1997) observed larger 
and prolonged circulating IL-6 concentrations following muscle damaging-eccentric exercise 
compared to that of concentric exercise (30 min at >100 % VO2max vs. 65 % VO2max, 
respectively). In their now classic work, this team of researchers suggested that peak IL-6 
concentrations following eccentric modalities were associated with elevated creatine kinase (CK) 
levels following exercise, depicting a possible dependency on muscle damage (Bruunsgaard, et 
al., 1997). The early assumptions that tissue damage serves as a prime initiator have now been 
rebutted by multiple groups of investigators that observed a much more prominent peak in IL-6 
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concentration following concentric exercise compared to previously executed eccentric models 
(~100-fold vs. ~5-fold) (Ostrowski et al., 1999). Ostrowkski, et al., (1999) observed peak CK 
levels 24 hours post concentric exercise with no relationship between peak IL-6 levels and peak 
CK levels (Ostrowski et al., 1999). Additionally, it is well established that adhesion molecules 
following muscle damage attract leukocytes to the inflamed location and IL-6 when acting as a 
cytokine signaler from immune cells stimulates the binding of adhesion molecules to leukocyte 
and endothelial cells (Akimoto, et al., 2002; Chen et al., 2006, Kaplanski, et al., 2003). Yet, 
published findings from multiple research teams report unaltered expression of adhesion molecules 
following exercise despite an exercise induced IL-6 increase, indicating two things: 1) IL-6 
production occurs independent of muscle damage and 2) IL-6 production during/following 
exercise exhibits an alternate function than that of traditional cytokine processes (Smith et al., 
2000, Chaar, et al., 2011). Accordingly, the more novel idea of circulating IL-6 post-exercise, does 
not negate the well-established fact that muscle damaging eccentric exercise likely initiates more 
traditional cytokine actions of IL-6 from immune cells. As such, dynamic exercise with a 
concentric emphasis provides muscle-derived IL-6 release into circulation; a response that appears 
to be largely independent of inflammation. 
IL-6 is expressed, produced and released from skeletal muscle. Ostrowski, et al., (1998b) 
as well as Steensberg et al. (2000) were frontrunners in identifying IL-6 release directly from 
skeletal muscle in response to exercise. More recent research indicates vesicles at the sarcolemma 
and T-tubule that contain IL-6 protein, which upon muscular contraction decrease in content 
(Lauritzen, et al., 2013). Bente Pedersen and colleagues (2003) were an innovative team of 
researchers who coined the term “myokine.” A myokine is described as a hormone-like protein 
produced, expressed and released from skeletal muscle tissue (Pedersen et al., 2003). Similar to 
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cytokine function, IL-6 is currently the most thoroughly studied myokine. Early attention given to 
IL-6 is appropriate in that a post-exercise spike in circulating IL-6 precedes the appearance of other 
myokines. To this end, IL-6 appears in circulation within 10 min of exercise (Macdonald, et al., 
2003, Nieman, et al., 2007). Unlike its cytokine functions, the time course of skeletal muscle 
derived IL-6 release and disappearance in circulation is transient, with levels returning to baseline 
within two hours post-exercise. Furthermore, production via skeletal muscle fibers during exercise 
does not activate pro-inflammatory pathways (Pedersen & Febbraio, 2008). For example, 
monocytes produce and initiate the cytokine role of IL-6 during sepsis, yet monocytes do not 
express an increase in IL-6 protein during exercise (Moldoveanu, et al., 2000; Starkie, et al., 2001). 
IL-6 is produced from all fiber types of skeletal muscle, but IL-6 mRNA concentrations following 
exercise increase predominately in type II muscle fibers, which also contain higher glycogen 
content. While this is not fully understood, early scientific speculation demonstrates that type II 
fibers are central to the production of IL-6 during muscular contraction (Hiscock, et al., 2004). 
Supporting this tentative conclusion, McGinnis et al., (2015) observed in exercised muscle that 
fiber type specific IL-6 mRNA expression occurs. Tentative findings are supported by findings 
from real-time PCR (polymerase chain reaction) performed in skeletal muscles of the lower limb. 
Specifically, cardiomyocytes had the lowest expression while extensor digitorum longus (largely 
type II) contained the largest expression. With higher expression in type II fibers, it is clear that 
IL-6 release from skeletal muscle is influenced by exercise intensity due to type II (glycolytic) 
skeletal muscle fibers being highly recruited with increased exercise intensity (Yamano, et al., 
2010).  
Cell signaling is heavily influenced by cytokines in a vast range of bodily processes. Over 
expression of certain cytokines occurs in numerous disease states, highlighting the importance of 
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investigating the regulatory processes in which these substances are involved. Cytokine secretion 
is not limited to immune cells, as seen by IL-6 production from skeletal muscle during and 
following exercise. A body of published data underpins a growing consensus that skeletal muscle 
acts in endocrine fashion, highlighting the prospect of distinct IL-6 signaling pathways involved 
with organ cross-talk (Pedersen & Febbraio, 2008). Collectively, a wealth of knowledge 
surrounding exercise and IL-6 signaling depicts specific responses to other cytokines, exercise 
duration, exercise intensity, as well as glucose and glycogen availability.  
 
Relationship between circulating TNF-α and IL-6 
The action of circulating IL-6 is altered when in the presence of TNF-α. TNF-α is a 
multifaceted inflammatory cytokine produced predominantly by macrophages, natural killer cells 
and lymphocytes (Clyde & Glaunsigner, 2010). Antagonists of TNF-α are effectively utilized to 
treat inflammatory disorders such psoriasis, rheumatoid arthritis and inflammatory bowel disease 
(Esposito, & Cuzzocrea, 2009). During severe infections (i.e. sepsis) and cardiometabolic disease, 
chronically elevated plasma concentrations of TNF-α and IL-6 are consistently observed 
(Pedersen, 2017). Upon stimulation, in scenarios such as sepsis, macrophages secrete a 
combination of pro-inflammatory cytokines: TNF-α, IL-1β and IL-6. Compared to sepsis, exercise 
results in different cytokine responses: transient increases of IL-6 with no acute increases in TNF-
α nor IL-1β. Rather, skeletal muscle derived IL-6 has downstream anti-inflammatory effects such 
as inhibition of TNF-α and stimulation of cortisol and anti-inflammatory cytokines IL-10 and IL-
1ra (interleukin-1 receptor antagonist) (Steensberg, et al., 2003). TNF-α is a potent inflammatory 
cytokine, and acts in union with IL-6 during inflammation (Pedersen, 2017). IL-6, unaccompanied 
by TNF-α, exhibits different and even anti-inflammatory effects. 
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IL-6 in response to exercise provides an anti-inflammatory environment by suppressing 
TNF-α. For instance, Starkie, et al., (2003) identified direct inhibition of TNF- α following exercise 
and recombinant IL-6 infusion. Researchers induced a low grade inflammatory state by 
administering E. coli to healthy subjects following 3h rest, 3h cycling or 3h infusion of 
recombinant IL-6. The intravenous bolus of E. coli resulted in a two- to three-fold increase in TNF-
α while subjects were at rest, however following exercise TNF-α was completely blunted. The 
exercise induced blunting effect of exercise was nearly identical to exercise independent IL-6 
infusion (eliciting same concentration as stimulated by exercise). These findings support the notion 
that IL-6 myokine action attenuates the appearance of TNF-α and may serve as a cytoprotective 
mechanism. In regards to metabolic function, TNF-α induces peripheral insulin resistance whereas 
recent findings indicate that IL-6 protects against metabolic damage and improves glucose 
tolerance (Plomgaard, et al., 2005; Carey, et al., 2006; Ellinsgaard, et al., 2008). IL-6 is no longer 
regarded as solely a synergist to TNF-α, with evidence indicating counter regulatory effects. In 
scenarios when TNF-α is not present, such as exercise, IL-6 undergoes phenomenological 
differences in magnitude, time and action than its customary cytokine roles (Reihmane et al., 2012; 
Steensberg, et al., 2002; Ostrowski, et al., 1998b).  
 
Tissue specificity and IL-6 signaling 
Actions of IL-6 are dependent on the source of production/release.  Cytokine and myokine 
properties of IL-6 are clearly differentiated by their unique upstream and downstream signaling 
cascades as seen by the altered pathways in skeletal muscle and immune cell (macrophages) IL-6 
secretion (Fig. 1). Stimulation of nuclear factor-kappaB (NF-kappaB) due to the activation of the 
TLR (toll like receptor) signaling cascade results in TNF-α, IL-1β and IL-6 release from 
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macrophages in scenarios such as sepsis. When produced in union with one another TNF-α, IL-1β 
and IL-6 act in synergy. However, upon muscular contraction IL-6 is not dependent on this 
stimulatory profile. Rather, the exclusive release of IL-6 from myocytes is suggested to be due to 
transcriptional control mediated by nitric oxide (NO) (Steensberg, et al., 2007).  Steensberg, et al. 
(2007) observed that inhibiting NO production during exercise attenuated IL-6 protein release. 
Further downstream pathways involve a distinguishing network of cellular interactions involving 
nuclear factor of activated T cells (NFAT) and/or p38 mitogen activated protein kinase (p38-
MAPK). Moreover, during exercise the sarcoplasmic reticulum releases calcium (Ca2+) resulting 
in muscular contractions. Lower intracellular concentrations of Ca2+, as seen during prolonged 
exercise, activates NFAT through the action of calcineurin (Im & Rao, 2004). NFAT expression 
is substantially higher in skeletal muscle compared to other cell types and NFAT has been shown 
to increase IL-6 mRNA expression within human muscle cells (Keller, et al., 2006). In addition to 
the sustained fatiguing mechanism of lowered Ca2+ during long durations, decreased fuel reserves 
(i.e. glycogen) is important. Prolonged exercise decreases muscle glycogen content, which in turn 
increases the phosphorylation of p38 MAPK within nuclei (Chan, et al., 2004). To this end, 
inhibition of p38 MAPK phosphorylation decreases IL-6 mRNA expression in muscle tissue 
(Chan, et al., 2004). Fatigue processes associated with exercise appears to be a potent stimulus of 
IL-6 production from skeletal muscle. In addition to source of production and receptor type, the 
unique myokine production pathways of IL-6 further highlight the difference between traditional 
cytokine processes.  
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Figure 1. Differences between macrophage and skeletal muscle stimulation of IL-6 release into circulation. Adapted 
from Pedersen & Febbraio, 2008. 
 
IL-6 production from various cell types initiates subsequent action on target tissues via 
unique receptor complexes. Receptor complexes, source of production as well as upstream and 
downstream signaling pathways influence IL-6 action. IL-6 has two receptor-mediated signaling 
approaches, referred to as classic signaling and trans-signaling (Fig. 2). In classic signaling, 
activity of IL-6 is mediated via two membrane bound proteins; the ligand-binding receptor (IL-
6R) and the signal transducing glycoprotein-130 (gp130) (Kishimoto, 1992). All mammalian cells 
display the gp130 on their cell membranes, thereby eliciting downstream effects on various cell 
types (Scheller, et al., 2011).  However, not all cells express the membrane bound IL-6R, thus the 
importance of having another signaling mechanism, trans-signaling. Components of this alternate 
pathway comprise of an extracellular soluble IL-6 receptor (sIL-6R) formed primarily via 
proteolytic shedding of the membrane bound IL-6R (Scheller, et al., 2011). Whether classical or 
trans-signaling occurs, the complex of the receptor and gp130 leads to the signal transduction of 
IL-6 which then activates the pathways: JAK/STAT (janus kinase/signal transducer and activator 
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of transcription), ERK (extracellular signal-regulated kinase), and PI-3K (phosphoinositide 3-
kinase).  
 
Figure 2. IL-6 classical and trans-signaling. Proteolytic shedding of the membrane bound receptor results in a soluble 
IL-6 receptor that then binds to gp130 and produces signal transduction of JAK/STAT, ERK, PI-3K pathways which 
activate transcription factors. Adapted from Reihmane & Dela, 2014. 
 
Recently published preliminary evidence suggests that IL-6 activates different upstream 
and down-stream signaling pathways leading to specific cellular interactions, clarifying the 
discrepancy between cytokine and myokine functions. Skeletal muscle derived IL-6 signals the 
myocardium post-exercise through alternate pathways compared to cytokine signaling. 
Downstream of the IL-6R/gp130 complex, IL-6 signaling pathways are different when IL-6 is 
secreted as a cytokine versus a myokine (Fig. 3). During ischemic preconditioning (IPC) trials, IL-
6 acts through the JAK/STAT and PI-3K pathways initiating protection from ischemic reperfusion 
injury (I/R) by activating downstream IPC mediators iNOS (inducible nitric oxide synthase) and 
COX-2 (cyclooxygenase-2). McGinnis, et al. (2015) observed that following exercise 
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preconditioning and subsequent I/R, IL-6 did provide protection from myocardial necrosis, 
however not through traditional cytokine signaling. Following exercise, investigators observed 
that JAK/STAT and PI-3K pathways did not initiate the protective effects (downstream activation 
of COX-2 and iNOS) of IL-6 signaling within the heart. Based on these findings, one might infer 
that exercise induced release of IL-6 follows an alternative route by which the myokine IL-6 
initiates transcription. Further discussion of these novel findings will be provided in a later section 
(Cardioprotection), due to the ground breaking notion that skeletal muscle derived IL-6 exhibits 
endocrine properties albeit through unidentified signaling pathways. In addition to the apparent 
differences in myokine and cytokine signaling within the myocardium, secretory pathways of IL-
6 change from immune cells to myocytes. 
 
Figure 3. Cytokine signaling compared with myokine signaling as proposed by McGinnis et al., (2015). 
As a generalization, the sIL-6R is associated with undesirable processes while the 
membrane bound IL-6R is more often associated with beneficial effects on homeostasis. For 
instance, pro-inflammatory effects of IL-6 are mostly mediated by trans-signaling (Kraakmen et 
11 
 
al., 2013; Rose-John, et al., 2007, Kraakmen et al, 2015). Early conclusions are supported by the 
observation that blockage of IL-6 trans-signaling in mice resulted in decreased inflammation in 
atherosclerosis (Scheutt, et al., 2012). Furthermore, use of tissue-specific deletion of membrane 
bound IL-6R (classical signaling) in murine hepatocytes, mice demonstrated detrimental 
metabolic phenotypes in regards to insulin resistance and glucose intolerance and liver 
inflammation (Wunderlich et al., 2010; Mauer et al., 2014). However, caution is warranted from 
broad based conclusions since the respective roles of membrane bound and soluble IL-6 receptor 
activation are still being defined in the context of myokine stimuli. Case in point, in addition to 
increasing circulating IL-6 protein, exercise also increases both membrane bound IL-6R and the 
sIL-6R in plasma and skeletal muscle (Leggate, et al., 2010; McGinnis, et al., 2015). The 
production of this myokine is heavily influenced by fatigue mechanisms, which are stimulated by 
higher intensity and longer duration exercise. The phenomenological differences between IL-6 
cytokine and myokine signaling have yet to be completely resolved. However, the upstream and 
downstream signaling pathways accompanied by the alternate receptor complexes provide a solid 
foundation in identifying fundamental differences between cytokine and myokine actions. 
 
Role of exercise intensity and duration on IL-6 production 
 The magnitude in the spike of circulating IL-6 during and post-exercise appears to be 
influenced by the amount of muscle mass recruited. Running, which recruits a large amount of 
muscle mass by virtue of lower and upper body movement, typically results in the largest 
circulating spike in post-exercise IL-6 (Nieman et al., 1998, Starkie, et al., 2000, 2001, Ostrowski, 
1998b). In agreement, exercise limited to the upper extremities does not produce a dramatic IL-6 
elevation post-exercise (Bergfors, et al., 2005; Hirose, et al., 2004). Although the amount of 
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contracting skeletal muscle influences IL-6 magnitude within circulation, the intensity and 
duration of exercise are the most potent stimulators of IL-6 production, independent of modality. 
With higher intensity and longer duration, human skeletal muscle performance is hindered by 
inevitable fatigue. As noted earlier, muscular fatigue is a powerful promoter of IL-6 release from 
skeletal muscle. 
 
Intensity 
Elevated levels of IL-6 are consistently observed following strenuous exercise indicating 
the influence of exercise intensity on IL-6 production. For instance, early published findings 
indicate a two-fold increase in plasma IL-6 following 6 min of “all out” rowing at a workload of 
400 watts (Nielsen, et al., 1996). Similar findings of a mild increase were observed following 2 
hours of whole body resistance training consisting of four sets of ten repetitions at 40-60% 1RM 
(1 set at 40% and 3 at 60% 1RM). A six-fold increase in plasma IL-6 from pre to post-exercise 
was observed (Nieman, et al., 2003). Later investigations revealed that IL-6 release is directly 
influenced by exercise intensity (Helge et al., 2003; Ostrowski et al., 2000). Helge et al. (2003) 
reported that plasma IL-6 concentrations increased proportionally to exercise intensity with a main 
effect of p < 0.05. Subjects performed double knee extension for 45 min at 25% Wmax followed by 
an additional 35 min where one leg exercised at 65% Wmax and the other at 85% Wmax. Using the 
Fick principle (femoral arterial-venous difference X blood flow) researchers identified differences 
in IL-6 release between both legs. The highest IL-6 release was observed at 85% Wmax, eliciting 
nearly a six-fold increase from resting values (p <0.05), whereas release at 65% and 25% Wmax did 
not exceed a three-fold increase. Notably, at both intensities (65% and 85% Wmax) IL-6 release 
increased over time, suggesting a positive associative relationship with exercise duration.  
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Duration  
The majority of plasma IL-6 elevations following exercise is attributed to exercise duration 
(Fischer, 2006). Rest intervals do not significantly affect IL-6 production as seen by Nieman et al. 
(2007). Nieman, et al., reported a 40-fold increase in plasma IL-6 concentrations in both 
continuous and intermittent exercise groups where individuals cycled for 2 hours at an intensity of 
75% VO2max. Comparatively, a mere five-fold increase in arterial IL-6 concentrations was 
observed after cycling for 1 hour at a similar intensity; 70% VO2max (p < 0.05) (Macdonald, et 
al., 2003). Ostrowski et al. (1998a) observed during treadmill running at 75% VO2max that 
circulating IL-6 levels were elevated 30 min into the bout (four-fold increase from rest) but peaked 
at 2.5 hr of exercise (25-fold from rest), supplying further evidence that increases in plasma IL-6 
during exercise are largely affected by duration. Ostrowski and colleagues continued their 
investigation, by observing IL-6 response following a marathon, where IL-6 levels increased 
markedly following the race (completion time: 3hr 17min ± 7.39 min) (Ostrowski, et al., 1998b). 
IL-6 plasma concentrations collected immediately post-race, revealed a near 100-fold increase 
from 1.5 ± 0.7 at rest to 94.4 ± 12.6 pg/ml. In the same study a significant decline in IL-6 plasma 
concentration was observed 2 hour post-exercise, resulting in 22.1 ± 3.8 pg/ml, elucidating the 
transient response to exercise. Another group of researchers observed similar findings of a 100-
fold increase in plasma IL-6 post marathon, (mean finish time = 2hr 37min) (Suzuki, et al., 2003). 
Contrarily, other teams of investigators failed to report the same magnitude of IL-6 appearance 
following marathon running (Bernecker, et al., 2013; Nieman, et al., 2001). The large disparity 
among finish times between the two sets of studies (1-1.5 hr) may be the mitigating factor behind 
the different amplitudes of circulating IL-6, although sample collection and handling are also likely 
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explanations. Nonetheless, IL-6 secretion from skeletal muscle is heavily influenced by the length 
of exercise and when combined with a higher intensity the largest release is observed.  
 
Influence of glucose and glycogen availability 
With longer duration and higher intensity of exercise active human skeletal muscle will 
inevitably achieve some degree of glycogen depletion. Ostrowski et al., (1998a) revealed that 
while exercising at 75% VO2max, the highest concentrations of plasma IL-6 occurred at 2.5 hr, a 
time point at which total glycogen depletion is imminent. Thus, appearance of IL-6 likely reflects 
the energy status/fatigue level of skeletal muscle, i.e. glycogen availability. Data from Steensberg 
et al. (2001) as well as Macdonald, et al. (2003) support this hypothesis, where larger release of 
IL-6 from skeletal muscle occurred in a glycogen depleted state.  
Muscle glycogen stores as well as exogenous glucose affect the magnitude of IL-6 release 
from skeletal muscle during exercise. Many published findings report a blunting effect of IL-6 
following ingestion of carbohydrates (CHO). In this regard, when fed CHO during 3 hours of 
running, participants exhibit lower plasma IL-6 concentrations compared to their non-CHO fed 
counterparts (Nieman, et al., 2003). A number of additional studies where endurance athletes 
where fed CHO (6% in solution), also resulted in lowered circulating IL-6 (Nehlsen-Cannarella, 
et al., 1997; Nieman, et al., 2001; Nieman, et al., 1998). However, Nieman et al. (2003) reported 
no difference in plasma IL-6 concentrations between a CHO fed group and a control group 
following 2 hr of heavy resistance training. However, the extent of circulating IL-6 did not reach 
that of the previously mentioned studies, therefore endogenous CHO may only attenuate IL-6 
release at a certain magnitude. 
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Muscle glycogen content is a powerful stimulus for IL-6 release from muscle. While 
performing one legged exercise (40% Wmax), Steensberg et al. (2001) observed that a significant 
net release of IL-6 from a glycogen depleted leg (40% less, p < 0.05) occurred 1 hr before an 
elevation in IL-6 was observed in a non-depleted exercised leg (4.38 ± 2.80 ng . min-1 vs. 0.36 
± 0.14 ng . min-1, respectively). Moreover, following a randomized cross-over design (two week 
washout), subjects cycled for one hour at 70% VO2peak where muscle biopsies were taken from 
the vastus lateralis (opposite legs for respective trials). Higher IL-6 release was observed at each 
10 min increment in glycogen depleted trials compared with high glycogen trails (p < 0.05) 
(Macdonald et al., 2003).  
Although IL-6 mRNA is influenced by glycogen availability, circulating IL-6 exhibits the 
strongest associations. For example, muscle glycogen depletion (vastus lateralis, 35.3 ± 4.2%) 
following treadmill running for 2.25 hr (70% VO2max) was inversely correlated with plasma IL-
6 concentrations (r= -0.72, p <0.001), yet it was not significantly associated with skeletal muscle 
IL-6 mRNA post-exercise (r = -0.211, p = 0.321) (Nieman, et al., 2015). In a subsequent study 
where subjects performed a 75 km cycling time trial (169 ±  26 min), depleted muscle glycogen 
stores (vastus lateralis, 77.2% ± 17.4%) were once again significantly correlated with the changes 
in plasma IL-6 (r = 0.462, p = 0.04) (Nieman, et al., 2016). Interesting to note, plasma IL-6 
concentrations in both of these studies increased roughly 40-fold during similar durations and 
intensity, yet muscle glycogen concentrations were substantially different within the biopsied 
muscle. These puzzling results may be attributed to two mechanisms: 1) running recruits more 
muscle mass resulting in a larger systemic release of IL-6 and 2) cycling isolates the vastus lateralis 
more so than running, resulting in a larger glycogen depletion and subsequent IL-6 release. IL-6 
levels in circulation are related to muscle glycogen content, however there are other elusive fatigue 
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mechanisms/pathways that may influence IL-6 production. The effect of glucose and glycogen 
availability on IL-6 production led to the understanding of IL-6 having a mediatory role in glucose 
metabolism. In this regard, prolonged exercise results in IL-6 inhibition of glycogen synthase while 
glycogen phosphorylase activity is promoted (Kanemaki, et al., 1998). Collectively, these findings 
suggest that IL-6 in circulation during/following exercise is highly influenced by glycogen 
depletion and glucose availability.  
 
IL-6 as a metabolic regulator  
Early evidence suggests that IL-6 may serve as a bioenergetic regulator, and exhibits roles 
within substrate metabolism. In support, mice lacking IL-6 expression develop mature onset 
obesity as well as elevated basal glucose levels in accordance with impaired glucose tolerance 
(Wallenius, 2002). Furthermore, in humans, infusion of IL-6 induces intramuscular as well as 
whole body lipolysis and fat oxidation (van Hall, et al., 2003; Wolsk, et al., 2010; Bruce et al., 
2004; Petersen, et al., 2005). When released in a fasted state, IL-6 mediates free fatty acid 
mobilization (Wueest, et al., 2014). Although, IL-6 alters fat metabolism, other evidence points 
towards a more central role within CHO metabolism during exercise. IL-6 clearly influences 
glucose kinetics at rest and during exercise. In a dose dependent manner, infusion of recombinant 
human IL-6 increased whole body glucose oxidation within human subjects (Stouthard et al., 
1995). Furthermore, Steensberg et al. (2001) concluded that a relationship exists between increased 
glucose uptake and net IL-6 release during exercise at low intensities (40% Wmax). If correct, this 
notion is consistent with subsequent observations which indicate a positive correlation exists 
between IL-6 release and glucose uptake at 25% Wmax was observed (R = 0.82, p = 0.03) (Helge 
et al. 2003). Accrued evidence demonstrates that IL-6 increases the delivery of glucose, glucose 
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uptake, lipolysis and fatty acid oxidation via 5’-adenosine monophosphate-activated protein kinase 
(AMPK).  
AMPK is central to metabolic responses to exercise via stimulation of fatty acid oxidation, 
glucose uptake and GLUT4 translocation (Ruderman, et al., 2006; Kahn, et al., 2005; Fisher, et 
al., 2002). IL-6 directly affects AMPK activity within skeletal muscle and adipose tissue, 
subsequently influencing substrate utilization (Kelley, et al., 2004; Carey, et al., 2006). Infusion 
of IL-6 results in insulin stimulated whole body glucose uptake, increased glucose oxidation as 
well as exercise induced whole body glucose production (Carey, et al., 2006; Febbraio, et al., 
2004). As little as 1 ng/ml of IL-6 elicits 2-fold increases GLUT4 translocation within skeletal 
muscle (Carey et al., 2006). Additionally, GLUT4 content in inguinal white adipose tissue of IL-
6 KO mice reduced post-exercise, indicating that IL-6 contributes to the regulation of CHO 
metabolism in adipose tissue in addition to skeletal muscle (Knudsen, et al., 2015; Knudsen, et al., 
2017). IL-6 appears to influence metabolic regulation and it is likely that IL-6 has an integral role 
within glucose metabolism at rest, during and post-exercise. In addition to enhancing AMPK, IL-
6 also influences pyruvate dehydrogenase (PDH) activity (Bienso, et al., 2014; Gudiksen, et al., 
2016). 
PDH is central in the regulation of substrate utilization, with higher activity leading 
towards more CHO usage (Mourtzakis, e al., 2006). In mouse models (C57BL/6), injection of IL-
6 reduced pyruvate dehydrogenase (PDH) activity within skeletal muscle in a fed state but 
increased PDH in a fasted state (Bienso, et al., 2014). These findings suggest that IL-6 exerts 
physiologic influence on glucose metabolism differently when fed or fasted. As such, IL-6 release 
appears to be part of complex concert of processes responsible for sensing whole body fuel 
availability. Such as, IL-6 may assist in signaling the hypothalamus, like leptin, influencing whole 
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body fuel balance (Wueest, et al., 2014). Concomitantly, IL-6 function is associated with altered 
PDH activity during prolonged exercise. PDH activity is reported to be higher within IL-6 KO 
mice, suggesting more CHO utilization. Gudiksen, et al., (2016) observed higher skeletal muscle 
PDH levels within IL-6 skeletal muscle-specific KO mice at rest and at 60 min of exercise 
compared to littermate floxed controls (p < 0.05). Additionally, in a sub study conducted by 
Gudiksen and colleagues, mice lacking IL-6 ran for a shorter duration (> 10 min, p < 0.05) during 
a graded exercise test to exhaustion. These findings suggest that IL-6 is in some way incorporated 
in the overall regulation of CHO fuel usage at rest and during exercise, specifically sparing CHO 
during prolonged exercise resulting in a longer durations.  A role for IL-6 in CHO metabolism is 
not exclusive to skeletal muscle, with evidence suggesting that IL-6 communicates with the liver 
in an effort to regulate glucose availability. Bertholdt, et al. (2017) utilized skeletal muscle tissue-
specific deletion of IL-6 to identify an influence on hepatic CHO metabolism. At rest, IL-6 KO 
compared to wild type mice had higher PDH activity within the liver. Following 120 min of 
exercise, hepatic glucose was significantly lower in IL-6 KO mice (p < 0.05). Taken together, these 
data indicate that skeletal muscle IL-6 influences hepatic CHO oxidation at rest and hepatic 
glucose release during exercise (Bertholdt, et al., 2017). All in all, research involving IL-6 and 
metabolic regulation provide new insights into the orchestration of metabolic processes between 
skeletal muscle and other tissues.  
Emerging data suggests myokine functions of IL-6 may assist in regulating CHO 
metabolism at rest as well as immediately following exercise. Influence on AMPK and PDH 
highlights a role for IL-6 within substrate utilization. Evidence does not indicate that CHO 
metabolism is dependent on IL-6, rather, IL-6 likely serves as a potentiator of the foundational 
roles of CHO regulation. IL-6 has been observed to influence insulin activity and improve GLUT4 
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transport post-exercise, hinting at a protective role in regards to glucose tolerance. Furthermore, 
numerous studies applying knock-out models have reported adverse metabolic profiles within 
rodents lacking skeletal muscle IL-6. 
 
Protection against metabolic stress 
Skeletal muscle derived IL-6 likely contributes to cytoprotection against metabolic stress 
by improving glucose tolerance, enhancing insulin sensitivity and preventing pancreatic cell 
damage. Although chronically elevated plasma IL-6 exist in low grade inflammatory states such 
as obesity and type 2 diabetes IL-6 however is accompanied by TNF-α as well as IL-1β in these 
states. Both TNF-α and IL-1β are detrimental to one’s metabolic profile. IL-1β is responsible for 
pancreatic β-cell damage within type 2 diabetes and inhibiting IL-1β, pancreatic β-cell dysfunction 
and glucose homeostasis is attenuated (Eguchi, et al., 2013; Ehses, et al., 2007). TNF-α is a prime 
actor within peripheral insulin resistance (Hotamisligil, et al., 1996; Uysal, et al., 1997). 
Specifically, TNF-α inhibits the phosphorylation of a vital substrate within the insulin signaling 
cascade of GLUT4 translocation (Plomgaard, et al., 2005). Exercise induced IL-6 release inhibits 
both of these detrimental cytokines upon infusion and exercise (Starkie, et al., 2003, Steensberg, 
et al., 2003). In addition to blocking these damaging cytokines, IL-6 enhances insulin’s action 
post-exercise and at rest. 
Insulin sensitivity increases with repeated exercise bouts and is enhance immediately post-
exercise (King, et al., 1988; Wojtaszewski, et al., 2000). Carey et al (2006) specifically observed 
that IL-6 infusion results in insulin stimulated glucose uptake. Furthermore, increased IL-6 levels 
following exercise also stimulates glucagon-like peptide-1 (GLP-1) secretion from pancreatic β-
cells consequently improving insulin secretion (Ellingsgaard, et al., 2011). The influence of IL-6 
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on insulin not only provides a mechanism to replenish energy stores post-exercise but it may serve 
as protective mechanism against metabolic damage.  
IL-6 prevents α-cell apoptosis as a result of metabolic stress, indicating protection against 
successive metabolic stressors (Ellingsgaard, et al., 2008). Additionally, IL-6 is reported to 
stimulate pancreatic α-cell proliferation and regulation (Ellingsgaard, et al., 2008).  Impaired IL-6 
signaling within hepatocytes leads to liver inflammation as well as insulin insensitivity 
(Wunderlich, et al., 2010). Upon deletion of the membrane bound IL-6 receptor from hepatocytes, 
glucose tolerance is reduced due to mitigated insulin-stimulated glucose transport within skeletal 
muscle and fat (Wunderlich, et al., 2010). Although IL-6 appears to have beneficial outcomes on 
metabolic homeostasis, over-expression of IL-6 exerts detrimental effects on liver and muscle 
metabolic function due to hyperinsulinemia and decreased glucose uptake (Franckhauser, et al., 
2008).  Using an electro-transfer in C57 mice, chronic overexpression of IL-6 resulted in a marked 
inflammatory state within the liver with reported increases in serum amyloid A, TNF-α and SOCS-
3 (suppressor of cytokine signaling) gene expression (p < 0.05) (Franckhauser, et al., 2008).  IL-6 
overexpression also resulted in elevated levels of insulin within beta cells accompanied by reduced 
glucose production from the liver. Furthermore, skeletal muscle metabolic function was 
significantly altered as observed by reduced glucose uptake and GLUT-4 content as well as 
decreases in mitochondrial genes: COX-2, ATP synthase and PGC1-α (p < 0.05) (Franckhauser, 
et al., 2008). In addition, Kubaszek et al., (2003) identified a specific polymorphism within the 
promoter region of the IL-6 gene in which individuals who possessed it had lower rates of whole-
body glucose uptake and exhibited more resistance to insulin administration.  
Together, these findings suggest further evidence that IL-6 is influential within CHO 
metabolism. While overexpression of IL-6 appears to be detrimental, skeletal muscle derived IL-
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6 appears to have the ability to provide cytoprotection by battling TNF-α and IL-1β, enhancing 
insulin and GLUT-4 action as well as promoting beneficial pancreatic function. In addition to 
metabolic protection, IL-6 provides protection against ischemic bouts within the myocardium, as 
seen by lessened necrotic tissue, and decreased markers of autophagy and apoptosis (McGinnis, et 
al., 2015). Interestingly, the specific biological processes due to IL-6 are likely to be stimulus-
dependent in that exercise and ischemic preconditioning evoke different outcomes in terms of 
indirect markers of autophagic and apoptotic involvement (McGinnis, et al., 2015; Smart, et al., 
2006; Dawn, et al., 2004; Matsushita, et al., 2005).  
 
Future horizons 
The ubiquitous nature of IL-6 is now well documented in a wealth of diverse research 
findings from basic science to integrative physiology. Most recently, efforts have led to the 
discovery of potential cytoprotective effects of skeletal muscle derived myokines. For instance, 
IL-6 improves insulin action following exercise and likely protects against metabolic damage due 
to its inhibitory effects on TNF-α and IL-1β. Aside from findings of IL-6 facilitating protection 
from metabolic stress, recent evidence reveals potential cardioprotective properties. Different 
genotypes of IL-6 exist, facilitation a new area of genetic and epigenetic research. With over 
expression leading to disease states and the transient increases post-exercise exerting metabolic 
benefits comes the question of whether or not certain individuals are at risk for disease due to more 
or less expression of IL-6. 
 
IL-6 Genotype Alterations  
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Polymorphisms within cytokines are hypothesized to influence disease prevalence and 
progression. Also, among the many exercise protocols reviewed, a majority reported large standard 
deviations of plasma IL-6 concentrations within subjects, suggesting a responder versus non-
responder effect, a polymorphism may contribute to these observations (Nieman, et al., 2016). In 
an effort to identify genetic predisposition to elevated IL-6 expression, Fishman et al., (1998) 
identified a polymorphism in the 5’ flanking region of the IL-6 gene. The 5’ flanking region is 
vital to the regulation of IL-6 gene expression. Researchers identified a single nucleotide alteration 
from the G allele to C allele at position -174 (rs1800795). In vivo observations of Fishman and 
colleagues indicated that the CC genotype resulted in lower IL-6 levels compared with the GC or 
GG genotype. However, conflicting evidence exists in regards to the effects of these 
polymorphisms. For instance, stimulation of monocytes with lipopolysaccharide resulted in higher 
IL-6 production within GC and CC compared to GG genotypes (Patel, et al., 2010). The C allele 
is associated with skeletal muscle damage following exercise and rhabdomyolysis (Funghetto, et 
al., 2013; Yamin, et al., 2008). Specifically, Funghetto, et al., (2013) observed higher IL-6 activity 
from zero to 48 hr post-eccentric exercise within CC and GC genotypes compared to GG. 
Together, findings suggest that the C allele may promote more cytokine and subsequent 
inflammatory actions. As mentioned earlier, Kubaszek et al., (2003) identified that subjects 
expressing the CC genotype display insulin resistance and higher serum glucose concentration. 
Individuals who expressed this CC genotype also exhibited lower energy expenditure along with 
higher BMI compared with the G allele. In agreement, a lower walking distance during the six 
minute walk test in elderly individuals was reported with individuals carry the C allele (p < 0.05) 
(Nicklas, et al., 2005). Although these results indicate polymorphisms in IL-6 promoter cites play 
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a role in IL-6 levels and ensuing effects, more research is needed to identify if these alterations in 
genotypes factor into the myokine and cytoprotective properties of IL-6.  
 
Cardioprotection 
IL-6 provides cardioprotection due to a regulatory role in ischemic pre-conditioning 
(McGinnis, et al., 2015; Smart, et al., 2006, Dawn, et al., 2004). An IL-6R gene single nucleotide 
polymorphism has been linked to the predisposition of atrial fibrillation and elderly individuals 
with GC genotype have been associated with higher levels of CVD and all-cause mortality (Lin et 
al., 2014; Bruunsgaard, et al., 2004). IL-6 can be deleterious, however, it plays a distinct role in 
the cardioprotective benefits of ischemic preconditioning (IPC). IPC is characterized as the process 
of administering brief ischemic episodes which then increases the heart’s ability to withstand 
ensuing ischemic reperfusion injury (I/R) (Dawn, et al., 2004).  Dawn et al. (2004) identified that 
IL-6 is necessary for beneficial IPC cardioprotection. Investigators identified IPC increases IL-6 
expression within cardiomyocytes. Increased expression of IL-6 was reported to be responsible for 
the activation of the JAK/STAT pathway and the succeeding increase in iNOS (inducible nitric 
oxide synthase) and COX-2 (cyclooxygenase-2), both of which are mediators of IPC. In IL-6 KO 
mice, researchers reported JAK/STAT suppression as well as abrogated expression of IPC 
downstream mediators, iNOS and COX-2. Furthermore, Smart et al. (2006) observed that pre-
treatment of IL-6 (10ng/ml) 24 hr prior to ischemic reperfusion injury (I/R) increased iNOS 
expression and induced a NO-dependent protective mechanism against reperfusion injury. More 
interesting, upon blocking the PI-3K pathway, both iNOS and the apparent IL-6 dependent 
protection were negated (Smart, et al., 2006). Data suggests that IL-6 acts through the canonical 
pathways JAK/STAT and PI-3K in order to provide the cardioprotective benefits of IPC. 
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Exercise prevents myocardial necrosis following I/R injury, although it is thought to 
provide protection through different mechanisms than that of IPC. The aforementioned work by 
McGinnis et al., (2015) served as groundwork in identifying inter-organ cross talk involving 
myokines and the myocardium. Specifically, an exercise protocol was implemented in an effort to 
identify if IL-6 produced from skeletal muscle signals the heart during the acute post-exercise 
period. Knowing the influence of IL-6 on IPC, investigators hypothesized that skeletal muscle 
derived/exercise induced IL-6 provides protection against I/R injury by signaling the heart. Upon 
analysis of exercised and non-exercised myocardium, there were no differences in COX-2 and 
iNOS between C57 wild type and IL-6 KO mice. Reports indicated that exercised wild type mice 
were protected against I/R injury 24 hr post-exercise as observed by the larger infarct areas and 
necrosis within exercised IL-6 KO mice (p = 0.049). Additionally, cleaved PARP (poly ADP-
ribose polmerase), a marker of cellular apoptosis, was lower within ischemic and perfused tissues 
of exercised wild-type mice compared to exercised IL-6 KO. Therefore, mice lacking IL-6 
appeared to suffer increased apoptosis following I/R, which is in agreement with findings from 
Matusushita, et al., (2005).  Autophagy marker, cardiac Atg3, was also altered depending on the 
presence of IL-6. For instance, ischemic as well as perfused tissue of exercised IL-6 KO mice had 
higher cardiac Atg3 compared to the sedentary IL-6 KO counterparts, while exercise  
C57 mice exhibited lower Atg3 levels when exercised. The difference in this autophagy marker 
further suggests that without IL-6 present, exercise does not provide the same levels of protection 
from I/R.  Furthermore, despite the same COX-2 and iNOS expression within exercised and non-
exercised mice, exercise protected against cardiac injury only in the mice that expressed IL-6. IL-
6 and its role in protection from I/R was believed to be dependent on COX-2 and iNOS action due 
to the IPC models of Smart, et al. (2006) and Dawn et al. (2004). However, results from the 
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McGinnis group shed light on the fact that IL-6 exerts protective effects during exercise 
precondition through an alternate pathway than that of IPC. IL-6 was suggested to possibly act 
through MAPK pathways due to the “protected” wild type exercised mice exhibiting larger p44/42 
MAPK and p38 MAPK expression compared with exercised IL-6 KO mice. More specifically, the 
increased MAPK levels were observed in both ischemic and perfused tissues, likely indicating that 
I/R did not cause the increased signaling, instead exercise preconditioning was the suggested 
source.  Following exercise the Quindry group (McGinnis, et al., 2015) observed transient 
increases of the membrane bound IL-6 receptor within the myocardium of wild type mice only, 
indicating that this myokine has the ability to signal the heart in an endocrine fashion. Taking the 
data from McGinnis et al. (2015), research should investigate the effects of IL-6 using tissue 
specific KO models targeting myocardial IL-6 receptor in addition to skeletal muscle IL-6. These 
exciting findings will propel future research into identifying additional cytoprotective capabilities 
of this myokine. Skeletal muscle derived IL-6 serves as an architype for understanding skeletal 
muscle’s endocrine capabilities, which will only continue to progress.  
 
Conclusions 
IL-6 exhibits alternate cellular actions when produced as a cytokine versus a myokine. 
Cytokine processes are mostly involved in inflammatory responses, such as infection and tissue 
damage following eccentric exercise. When produced directly from skeletal muscle, IL-6 acts in a 
different manner than when produced from immune cells. Differences in IL-6 action are attributed 
to IL-6 receptor signaling, location of production and subsequent upstream and downstream 
secretory pathways, as well as the presence of pro-inflammatory cytokines (TNF-α and IL-1β). 
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IL-6 is a myokine with the ability to deter pro-inflammatory cytokines, such as TNF-α and 
IL-1β, providing a protective mechanism against disease progression. When in the presence of 
TNF-α, IL-6 performs inflammatory processes. However, exercise induced increases in IL-6 are 
not accompanied by TNF-α, rather IL-6 has the capability to inhibit pro-inflammatory cytokines 
and stimulate anti-inflammatory molecules (Steensberg, et al., 2003). The anti-inflammatory 
effects of exercise, as seen via IL-6, suggest an acute yet potent mechanism to fight progression of 
low-grade inflammatory disease states, such as obesity and type 2 diabetes.  
IL-6 release from skeletal muscle during exercise is strongly influenced by the energy 
status of skeletal muscle. IL-6 elevations during endurance exercise are reduced when fed CHO 
and increased when glycogen stores are diminished (Nehlsen-Cannarella et al., 1997; Nieman et 
al. 1998; Nieman et al., 2001). In 2001, Starkie et al. published results indicating carbohydrate 
ingestion mitigated plasma IL-6. As such these findings suggest that when the body is supplied 
ample CHO, IL-6 is not produced significantly. Furthermore, exercising in a glycogen-depleted 
state elevates plasma IL-6 (Steensberg et al., 2001, Helge, et al., 2003, Nieman, et al., 2015, 
Nieman et al., 2016). From this evidence, there appears to be an interrelationship between IL-6 
and the energy state of active skeletal muscle although, the precise mechanisms are not fully 
understood. Collectively, a wealth of research has generated a developing hypothesis that IL-6 
production following exercise is dependent on fatigue of skeletal muscle by exercise duration, 
exercise intensity and ensuing glycogen depletion. Glycogen depletion is at the forefront due to 
data indicating IL-6 having vital roles within CHO metabolism at rest and during exercise. 
A mediatory role within substrate metabolism has been attributed to IL-6. IL-6 exerts its 
effects on metabolic processes via its influence on AMPK and in turn PDH. Infusion of IL-6 
initiates lipolysis and fat oxidation as well as glucose uptake. Action of IL-6 within metabolism 
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seems to depend on being in a fed or fasted state. Fasting induced free fatty acid mobilization is 
influenced by IL-6 activity (Wueest, et al., 2014). Meanwhile, IL-6 appears to play a more vital 
role in CHO metabolism as seen by IL-6-dependent increases of insulin stimulated GLUT4 
translocation and glucose uptake at rest and following exercise (Febbraio, et al., 2004; Carey et 
al., 2006). The influence on insulin activity leads to speculation of IL-6 and energy restoration 
processes post-exercise. In addition, IL-6 likely provides beneficial mechanisms at rest as well due 
to its influence on insulin stimulated glucose uptake. Evidence also suggests a protective role for 
IL-6 in metabolism due to proliferation and protective effects of pancreatic α-cells (Ellinsgaard, et 
al., 2008).  
In addition to inhibiting pancreatic α-cell apoptosis, IL-6 appears to be essential to the 
cardioprotective effects of a short term exercise regimen. McGinnis, et al., (2015) observed that 
the protection from ischemic reperfusion injury due to exercise preconditioning was dependent on 
IL-6. More specifically, this team suggested that skeletal muscle derived IL-6 influenced signaling 
within the heart in endocrine fashion protecting the myocardium from reperfusion injury. 
Subsequent research will use findings from McGinnis et al., (2015) in order to identify specific 
actions within the myocardium and other tissues in which IL-6 may induce protective mechanisms. 
The dogma surrounding the relationship between inflammation and IL-6 has long vanished with 
an abundance of research indicating anti-inflammatory effects, regulatory actions in metabolism 
and cytoprotective properties. 
 The roles of IL-6 in health and disease are partially understood through compelling recent 
evidence suggesting a valuable role of IL-6 (and exercise) in combating morbidity. Stated 
differently, exercise is medicine and the IL-6 response to exercise is one of the many factors that 
supports this notion. Exercise is a simple, yet effective treatment in mitigating inflammatory, 
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metabolic and cardiac damage (Pedersen, et al., 2017; Quindry, 2017). Due to the far reaching 
benefits of exercise participation, many individuals would benefit from protocols tailored toward 
stimulating IL-6 release from skeletal muscle. Diabetes, heart disease and obesity are three of the 
most prevalent disease states within the United States (PAGACR, 2008). Interleukin-6 has the 
capabilities to combat all three of these diseases. IL-6 regulates CHO metabolism and assist in 
glucose transport into skeletal muscle (Carey et al., 2006). Individuals suffering from diabetes 
could greatly improve their metabolic profile through exercise and the IL-6 response that come 
with it, due to the observed increase of insulin sensitivity and GLUT-4 translocation. Also, exercise 
induced IL-6 suppresses TNF-α and IL-1β, which not are “inflammatory cornerstones” in many 
disease states, including conditions provoked by obesity. By combating TNF-α and IL-1β, 
interleukin-6 (and exercise) reduces inflammation within numerous diseases. Furthermore, 
McGinnis, et al., (2015) reported exercised induced cardio protection 24 hr post-exercise, which 
was dependent on IL-6.  Other investigations report that IL-6 also protects against ischemic injuries 
during IPC trials (Dawn et al., 2004; Smart et al., 2006).  Skeletal muscle acts as an endocrine 
organ with IL-6 being the most investigated effector myokine to date. Future investigations into 
exercise myokines are needed to better understand the benefits of regular exercise. Next generation 
experiments will likely result in the eventual application of myokine-related exercise therapy 
prescriptions.  
Personalization of an exercise plan is crucial to establish an effective stimulus for IL-6 
release as well as ensure the safety of an individual. Due to a polymorphism within the promoter 
region of the IL-6 gene which may predispose an individual to a more pronounced response than 
others, the following guidelines are a general recommendation for any individual aiming to acquire 
the benefits of exercise and subsequent IL-6 release. Training methods should target the known 
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stimulus of IL-6 release; fatigue. High exercise intensity, long duration and low CHO availability 
are all methods of achieving fatigue, with a combination of these factors resulting in the most 
potent stimulus (Steensberg, et al., 2001; Ostrowski, et al., 1998; Leggate, et al., 2010; Nieman, et 
al., 2015, 2016). Concentric modalities result in the largest plasma IL-6 concentrations, with 
running eliciting the most prominent peaks during/post-exercise (Ostrowski, et al., 1998; Fischer, 
et al., 2006). With a greater number working muscles the larger an IL-6 response will be, which 
explains why running elicits some of the largest IL-6 concentrations in circulation (Nieman et al., 
1998, Starkie, et al., 2000, 2001, Ostrowski, 1998b). However, if running is not appropriate for an 
individual, one could easily adapt and isolate a specific muscle group. Isolation exercise(s) are an 
effective strategy due to an increased amount of glycogen depletion, as seen during cycling bouts 
(Nieman et al., 2016). A more advanced training tool to elicit glycogen depletion and subsequent 
IL-6 release would be two-a-days (Gollnick, Piehl & Saltin, 1974). For example, during the initial 
bout an individual could target their glycogen stores (fast glycolytic energy system) by training at 
a high intensity followed by an additional bout at a relatively high intensity once again in order to 
achieve a quicker and more pronounced IL-6 release from muscle which were likely depleted of 
glycogen in the initial bout. Thus, from the perspective of eliciting a rapid IL-6 spike post exercise, 
one might limit CHO-replenishing practices. To this end, strategic CHO feeding should be 
evaluation in ongoing research to better understand the influence on IL-6 myokine release 
(Nehlsen-Cannarella, et al., 1997; Nieman, et al., 1998; Nieman, et al., 2001; Nieman, et al., 2003).  
In regard to exercise intensity, evidence suggests that IL-6 release is more pronounced to type II 
fibers. Thus, to the end of promoting IL-6 release, it now appears that exercise protocols that 
consists of higher intensities due to type II fibers recruitment are most effective (Yamano, et al., 
2010; Hiscock, et al., 2004; McGinnis, et al., 2015). Therefore, models utilizing interval training 
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serve as an effective strategy to evoke an exercise induced IL-6 response. Specifically, high 
intensity interval training (HIIT) may be a beneficial option due to the increased demand of 
glycolytic sources and ensuing glycogen depletion and fatigue (Knuiman, et al., 2015). New 
investigations reported that HIIT elicits an IL-6 release, however responses are heavily influenced 
by the number of intervals or total duration (Leggate, et al., 2010). The specific concentration of 
IL-6 protein and therefore the amount of exercise needed for protective systemic effects remain 
unknown and almost certainly varies among individuals. However, it is important to recall that the 
cytoprotective benefits of an acute exercise bout are biochemical in nature and, as demonstrated 
by McGinnis, et al., (2015), extend at least 9 days after their last exercise bout. More studies are 
needed to identify how long these protective effects last in addition to clarifying the optimal 
concentrations of circulating IL-6 and amount of exercise to induce metabolic and 
cardioprotection. Aside from future investigations, engaged readers should advance this rationale 
being cognizant of the fact that exercise is an accessible, cost effective and widely beneficial 
strategy to combat various diseases; and that myokines such as IL-6 are just the “tip of the iceberg” 
in promoting pleiotropic health benefits.  
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